Clinical trials: HFpEF
Heart Failure, Congestive Heart Failure
Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint).
- Trial name
- NCT01516346
- Testing
- Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Heart Failure
NoYA RAISE Trial II (Radiofrequency Ablation-Based Interatrial Shunt for Heart Failure)
A Prospective, Multiple Center, and Objective Performance Criteria Study to Evaluate the NoYA™ Radiofrequency Interatrial Shunt System manufactured by NoYA Medtech (Hangzhou) Co., Ltd.
- Trial name
- NCT05375110
- Testing
- NoYA™ Radiofrequency Interatrial Shunt System
- Where
- 31 sites in China
- Volunteers
- 120 people
- Sponsor
- Hangzhou NOYA MedTech Co. Ltm.
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation
Exercise Capacity Before and After AF Ablation in Patients With HFpEF
In a prospective, observational pilot study of patients scheduled for an atrial fibrillation (AF) ablation at the University of Vermont Medical Center the investigators will compare exercise capacity before and four months after…
- Trial name
- NCT05376748
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Vermont
Cardiovascular Diseases, Heart Failure
The Safety and Efficacy of Pulsed Field Ablation for Patients With Persistent Atrial Fibrillation Comorbid With HFpEF.
The goal of this clinical trial is to evaluate the the mid- and long-term clinical efficacy and safety of pulsed field catheter ablation for patients with persistent atrial fibrillation and HFpEF.
- Conditions
- Cardiovascular Diseases, Heart Failure, Atrial Fibrillation (AF), HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT07077811
- Testing
- pulsed field ablation, antiarrhythmic drug
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Affiliated Hospital of Nantong University
Preeclampsia, Heart Failure Preserved Ejection Fraction
Exercise Testing After Preeclampsia
Though cardiovascular disease (CVD) is the leading cause of mortality in women, traditional epidemiology in this area has focused on later life, when cardiometabolic risk has already exacted a cumulative toll on the vascular…
- Conditions
- Preeclampsia, Heart Failure Preserved Ejection Fraction, Hypertension
- Trial name
- NCT06741436
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Acute Myocardial Infarction, Heart Failure With Preserved Ejection Fraction
Predictors and Outcomes of In-hospital HFpEF in AMI Patients
This retrospective observation is to investigate the incidence,clinical outcomes and prognosis of hospitalized heart failure with preserved ejection fraction (HFpEF) in patients with acute myocardial infarction(AMI).
- Conditions
- Acute Myocardial Infarction, Heart Failure With Preserved Ejection Fraction, Predictor, Prognosis
- Trial name
- NCT03351179
- Testing
- clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xiangjun Yang
Chronic Heart Failure
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
This is a multi-center, randomized, double-blind, placebo-controlled study in subjects with stable heart failure with preserved ejection fraction (HFpEF) to evaluate the effects of 4 weeks treatment with subcutaneous MTP-131…
- Trial name
- NCT02814097
- Testing
- elamipretide
- Where
- 9 sites in Germany, Serbia
- Volunteers
- 46 people
- Sponsor
- Stealth BioTherapeutics Inc.
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure, Pulmonary Hypertension
Rivet PVS Therapy in Group 2 PH-HFpEF Canada
This clinical investigation is a prospective, multicenter, non-randomized, open-label, Early Feasibility Study to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with…
- Trial name
- NCT05332873
- Testing
- Rivet Shunt
- Where
- Canada
- Sponsor
- NXT Biomedical
Heart Failure
Rehabilitation Program in Heart Failure With Preserved Ejection Fraction
The purpose of this prospective study is to determine whether comprehensive cardiac rehabilitation is superior to usual disease management in the treatment of patients with heart failure with preserved systolic function (HFpEF)…
- Trial name
- NCT01914315
- Testing
- Cardiac Rehabilitation, Internal Medicine
- Where
- 2 sites in Israel
- Volunteers
- 1,100 people
- Sponsor
- Sheba Medical Center
Heart Failure With Preserved Ejection Fraction (HFpEF)
DevElopMent of Clinical PATHwaYs to the Diagnosis of Heart Failure With Preserved Ejection Fraction
Prevalence of heart failure with preserved ejection fraction (HFpEF) continues to increase in the developed world, likely because of the increasing life expectancy and an increasing number of elderly patients.
- Trial name
- EMPATHY-HF (NCT05792059)
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Diastolic Heart Failure
Enhancement of Physical Activity in Elderly Patients With Diastolic Heart Failure by a Motivational Intervention
The aim of our pilot study is to evaluate the feasibility, acceptance and efficacy of motivational interviewing (MI) to support elderly patients with heart failure with preserved ejection fraction (HFpEF) in maintaining or…
- Trial name
- Ex-DHFadd-on (NCT03402490)
- Testing
- Motivational interviewing
- Volunteers
- 39 people
- Sponsor
- University of Göttingen
MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF)
Resmetirom in Patients With MASH and HFpEF
This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis…
- Trial name
- NCT07830758
- Testing
- Resmetirom
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Heart Failure, Heart Failure, Systolic
Predicting Heart Failure Outcomes With Biomarkers and Imaging
This study aims to develop a better model to predict one-year risk of death in patients with heart failure. We will test whether combining information from routine blood tests (like NT-proBNP) and heart scans (measuring features…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- BIOPHF (NCT07332520)
- Volunteers
- 4,000 people
- Sponsor
- Xinjiang Medical University
Anemia
Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
The purpose of this study is to determine if treating anemia with subcutaneous erythropoetin in patients with heart failure and a preserved ejection fraction (HFPEF) will be associated with reverse ventricular remodeling…
- Trial name
- NCT00286182
- Testing
- Erythropoietin alpha
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Mathew S. Maurer
Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFPEF)
Optimised Cardiovascular and Renal Protection in Patients With Chronic Kidney Disease and Cardiovascular Disease
The goal of this clinical trial is to investigate whether care in a specialised Cardio-Renal Clinic can improve the health of people living with both cardiovascular disease and chronic kidney disease.
- Conditions
- Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFPEF), Cardiovascular Diseases
- Trial name
- OPTICARE (NCT07835828)
- Testing
- Multidisciplinary Cardio-Renal Care
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- Odense University Hospital
Heart Failure, Diastolic, Heart Failure, Systolic
Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Heart failure (HF) is a syndrome, resulting from structural or functional impairment of ventricular filling or ejection of blood.
- Conditions
- Heart Failure, Diastolic, Heart Failure, Systolic, Pulmonary Hypertension, Atrial Fibrillation
- Trial name
- PRESMET (NCT05475028)
- Testing
- RRBS
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Heart Failure With Preserved Ejection Fraction
Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients
This research is being done to better understand the relationship between information collected by wearable devices and clinical measurements in people with heart failure with preserved ejection fraction (HFpEF) and others…
- Trial name
- NCT04998877
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Hypertension, Pulmonary, Heart Failure With Normal Ejection Fraction
Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
The primary objective of this study is to Assess the pharmacodynamic profile of riociguat in subjects with symptomatic pulmonary hypertension and heart failure with preserved ejection fraction The secondary objectives of this…
- Trial name
- DYNAMIC (NCT02744339)
- Testing
- Riociguat
- Where
- Austria
- Volunteers
- 118 people
- Sponsor
- Medical University of Vienna